- Muschen, Markus;
- Chang, BH;
- Johnson, K;
- LaTocha, D;
- Rowley, JSJ;
- Bryant, J;
- Burke, R;
- Smith, RL;
- Loriaux, M;
- Müschen, M;
- Mullighan, C
© 2015 Chang et al.; licensee BioMed Central.Background: Novel-targeted therapies are in rapid development for the treatment of acute lymphoblastic leukemia (ALL) to overcome resistance and decrease toxicity. Survivin, a member of the inhibitor of apoptosi
